10-K: BioCardia Reports FY 2024 Results, Focuses on CardiAMP Trials and Allogeneic MSC Therapy

BioCardia, a clinical-stage company, announces its FY 2024 results, highlighting progress in its CardiAMP cell therapy trials for heart failure and chronic myocardial ischemia, as well as its allogeneic MSC therapy platform.

Summary

• BioCardia, Inc. is a clinical-stage company focused on developing cell-based therapies for cardiovascular and pulmonary diseases.
• The company's lead product, the CardiAMP Cell Therapy System, is being evaluated in Phase III trials for ischemic heart failure with reduced ejection fraction (HFrEF) and chronic myocardial ischemia (CMI).
• BioCardia is also advancing an allogeneic mesenchymal stem cell (MSC) therapy platform for ischemic HFrEF and acute respiratory distress syndrome (ARDS).
• The company's autologous and allogeneic cell therapies are enabled by the Helix minimally invasive intramyocardial therapeutic delivery platform.
• In FY 2024, BioCardia reported a net loss of $7.9 million and had an accumulated deficit of $160.1 million as of December 31, 2024.
• The company's cash and cash equivalents totaled $2.4 million as of December 31, 2024, which is expected to fund operations until May 2025.
• BioCardia is seeking additional funding through equity or debt financings, collaborations, and licensing arrangements.
• The company is planning to present principal results from the CardiAMP HF trial at the American College of Cardiology (ACC) Scientific Sessions on March 30, 2025.
• The CardiAMP HF II trial, a Phase III study focusing on patients with elevated NTproBNP levels, is actively enrolling patients.
• The CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial is a Phase III study evaluating the therapy for patients with refractory angina.
• BioCardia is also progressing its CardiALLO allogeneic MSC therapy for ischemic HFrEF, with a Data Safety Monitoring Board review scheduled for the second quarter of 2025.
• The company is partnering with StemCardia and CellProthera to advance its Helix biotherapeutic delivery system.
• BioCardia received FDA market clearance for its Morph-DNA product family in August 2024.
• The company's revenue for FY 2024 was $58,000, while research and development expenses were $4.4 million and selling, general, and administrative expenses were $3.7 million.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is progress in clinical trials and partnerships, the company faces financial challenges and uncertainties regarding regulatory approvals and market acceptance.

Positives

• FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for heart failure.
• Phase III trials underway for CardiAMP in both ischemic heart failure and chronic myocardial ischemia.
• Allogeneic MSC therapy platform progressing with CardiALLO trial and IND approval for PulmALLO.
• Partnerships with StemCardia and CellProthera to advance Helix biotherapeutic delivery system.
• FDA market clearance for Morph-DNA product family.

Negatives

• History of operating losses and accumulated deficit of $160.1 million as of December 31, 2024.
• Limited cash reserves of $2.4 million as of December 31, 2024, expected to fund operations only until May 2025.
• Dependence on additional funding through equity or debt financings, collaborations, and licensing arrangements.
• Uncertainty regarding the success of clinical trials and regulatory approvals for therapeutic candidates.
• Limited commercialization experience and dependence on market acceptance of therapeutic candidates.

Risks

• Inability to obtain regulatory approvals for therapeutic candidates.
• Failure to achieve market acceptance of therapeutic candidates.
• Competition from other companies in the biotechnology and pharmaceutical industries.
• Reliance on third parties for manufacturing, research, and clinical testing.
• Potential product liability lawsuits and adverse events.
• Failure to comply with environmental, health, and safety laws and regulations.
• Dependence on key personnel and ability to attract and retain qualified employees.
• Potential system failures and cybersecurity threats.
• Uncertainties surrounding intellectual property protection and potential infringement claims.
• Volatile market price of common stock and potential delisting from Nasdaq.

Future Outlook

BioCardia plans to continue the pivotal CardiAMP autologous cell therapy trials in heart failure and chronic myocardial ischemia, and begin allogeneic cell therapy trials in heart failure and acute respiratory distress syndrome. The company is seeking additional funding through equity or debt financings, government or other third-party funding, marketing and distribution arrangements, and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches.

Industry Context

The biotechnology and pharmaceutical industries are highly competitive, with intense competition to develop new technologies and proprietary products. BioCardia faces potential competition from many different sources, including larger and better-funded companies. The company must compete with other companies focused on cell-based therapy treatments, as well as existing therapies and new therapies that may become available in the future.

Comparison to Industry Standards

• The document does not contain specific information to compare BioCardia's results to global benchmarks.
• The document does not contain specific information to compare BioCardia's results to specific comparible companies.
• The document does not contain specific information to compare BioCardia's results to specific projects.
• The document does not contain specific information to compare BioCardia's results to specific results.

Related Party Transactions

• In February 2024, we entered into a securities purchase and registration rights agreement relating to a private placement with certain qualified institutional buyers and institutional accredited investors, as well as Peter Altman, our President and Chief Executive Officer.
• In August 2024, we entered into a securities purchase agreement with certain purchasers. Pursuant to such agreement, we sold an aggregate of (i) 1,377,990 shares of our common stock and accompanying warrants to purchase an aggregate of 1,377,990 shares of our common stock at an offering price of $3.00 per share and accompanying warrant and (ii) pre-funded warrants to purchase an aggregate of 1,022,010 shares of our common stock and accompanying warrants to purchase an aggregate of 1,022,010 shares of our common stock at an offering price of $2.999 per pre-funded warrant and accompanying warrant. Certain of our 5% stockholders, directors, and executive officers invested in such offering as follows: entities affiliated with Thomas A. Satterfield, Jr. invested $210,000, Andrew Blank invested $333,000, Jim Allen invested $150,000, Peter Altman, Ph.D. invested $125,000, and David McClung invested $25,000.

Stakeholder Impact

• Shareholders: Dilution from potential equity financings, potential for increased value if clinical trials are successful.
• Employees: Job security dependent on company's financial performance and success of clinical trials.
• Patients: Potential for new treatment options for cardiovascular and pulmonary diseases.
• Suppliers: Continued business relationship dependent on company's financial stability and research and development activities.
• Creditors: Risk of default if company is unable to secure additional funding.

Next Steps

• Present principal results from the CardiAMP HF trial at the ACC Scientific Sessions on March 30, 2025.
• Continue enrolling patients in the CardiAMP HF II trial.
• Gather top line results of the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial roll-in cohort for publication and presentation.
• Conduct Data Safety Monitoring Board review of CardiALLO allogeneic MSC therapy for ischemic HFrEF in the second quarter of 2025.

Key Dates

Keywords

CardiAMP, cell therapy, heart failure, ischemia, allogeneic MSC, clinical trials, FDA, Helix, biotherapeutic delivery, financial results, Biocardia